Apellis Pharmaceuticals Inc - Company Profile
Powered by 
All the data and insights you need on Apellis Pharmaceuticals Inc in one report.
$295
- Save hours of research time and resources with
our up-to-date Apellis Pharmaceuticals Inc Strategy Report
- Understand Apellis Pharmaceuticals Inc position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
View up-to-date information on Apellis Pharmaceuticals Inc patents, including inventor and filing insights.
Patent Trends
| Publication Identifier | Document Type | Title | Classification-CPC | Publication Date |
|---|---|---|---|---|
| AU2021221035A1 | Application | RNAs for complement inhibition | A61K31/713; A61K45/06; A61K47/549; C12N15/113; C12N2310/14; C12N2310/343; C12N2310/346; C12N2320/11; C12N2320/30 | September 08, 2022 |
| US20220280598A1 | Application | COMPLEMENT INHIBITOR DOSING REGIMENS | A61K38/12; A61K47/60; A61K9/0019 | September 08, 2022 |
| AU2021206693A1 | Application | Treatment of paroxysmal nocturnal hemoglobinuria | A61K38/12; A61K39/3955; A61K47/55; A61K47/60; A61P7/00; C07K16/18; C12Q1/32; G01N2800/22; G01N2800/52; G01N33/721 | August 25, 2022 |
| HRP20131342T2 | Grant | LONG-ACTING COMPSTATIN ANALOGS AND RELATED COMPOSITIONS AND METHODS | A61K38/00; A61K38/005; A61K38/10; A61K47/542; A61K47/55; A61K47/60; A61P37/00; A61P37/06; A61P43/00; C07K14/472; C07K7/08 | August 19, 2022 |
| US20220249706A1 | Application | VIRAL VECTOR THERAPY | A61K48/0083; A61P21/00; A61P33/00; A61P7/00; C07K16/18; C07K2317/76; C12N15/86; C12N2750/14143 | August 11, 2022 |
Top Inventors by Filings (Count by publication)
| Name | Count |
|---|
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer